Vanda Pharmaceuticals (VNDA) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$394.8 million.
- Vanda Pharmaceuticals' Retained Earnings fell 12649.69% to -$394.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$394.8 million, marking a year-over-year decrease of 12649.69%. This contributed to the annual value of -$394.8 million for FY2025, which is 12649.69% down from last year.
- Per Vanda Pharmaceuticals' latest filing, its Retained Earnings stood at -$394.8 million for Q4 2025, which was down 12649.69% from -$253.6 million recorded in Q3 2025.
- Vanda Pharmaceuticals' Retained Earnings' 5-year high stood at -$153.0 million during Q3 2023, with a 5-year trough of -$394.8 million in Q4 2025.
- Over the past 5 years, Vanda Pharmaceuticals' median Retained Earnings value was -$168.7 million (recorded in 2022), while the average stood at -$186.5 million.
- In the last 5 years, Vanda Pharmaceuticals' Retained Earnings soared by 1680.05% in 2021 and then crashed by 12649.69% in 2025.
- Quarter analysis of 5 years shows Vanda Pharmaceuticals' Retained Earnings stood at -$164.2 million in 2021, then grew by 3.82% to -$157.9 million in 2022, then grew by 1.59% to -$155.4 million in 2023, then fell by 12.16% to -$174.3 million in 2024, then plummeted by 126.5% to -$394.8 million in 2025.
- Its Retained Earnings was -$394.8 million in Q4 2025, compared to -$253.6 million in Q3 2025 and -$231.0 million in Q2 2025.